Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase

(2015) Jaya Sangodkar et al.   FEBS Journal

Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia

(2015) Issam Arrouss et al.   PROTEIN AND PEPTIDE LETTERS

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies

(2015) Maria Ciccone et al.   Frontiers in Oncology

SETting OP449 into the PP2A-Activating Drug Family

(2014) P. Neviani et al.   CLINICAL CANCER RESEARCH

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Editorial (Thematic Issue: “Cell-penetrating Peptides and Drug Delivery”)

(2014) Yongzhuo Huang   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies

(2014) Inês Rego de Figueiredo et al.   IUBMB LIFE

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

(2014) Amy S. Farrell et al.   MOLECULAR CANCER RESEARCH

Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy

(2014) Issam Arrouss et al.   PLoS One

FTY720 Induces Apoptosis of M2 Subtype Acute Myeloid Leukemia Cells by Targeting Sphingolipid Metabolism and Increasing Endogenous Ceramide Levels

(2014) Limin Chen et al.   PLoS One

The Basic Biology of PP2A in Hematologic Cells and Malignancies

(2014) Dorien Haesen et al.   Frontiers in Oncology

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein Phosphatase 2A as a Potential Target for Anticancer Therapy

(2012) Peter Kalev et al.   Anti-Cancer Agents in Medicinal Chemistry

The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells

(2012) V. Janssens et al.   CURRENT MOLECULAR MEDICINE

APOE-Mimetic Peptides Reduce Behavioral Deficits, Plaques and Tangles in Alzheimer’s Disease Transgenics

(2012) M.P. Vitek et al.   Neurodegenerative Diseases

SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification

(2012) Andréia M. Leopoldino et al.   ORAL ONCOLOGY

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation

(2011) Yan Yang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

(2011) D. J. Christensen et al.   JOURNAL OF IMMUNOLOGY

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

Identification of PP2A Complexes and Pathways Involved in Cell Transformation

(2010) A. A. Sablina et al.   CANCER RESEARCH

Characterization of Bioactive Cell Penetrating Peptides from Human Cytochrome c: Protein Mimicry and the Development of a Novel Apoptogenic Agent

(2010) Sarah Jones et al.   CHEMISTRY & BIOLOGY

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

(2008) Archana Mukhopadhyay et al.   FASEB JOURNAL

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE

Characterization of a Novel Cytotoxic Cell‐penetrating Peptide Derived From p14ARF Protein

(2007) Henrik J Johansson et al.   MOLECULAR THERAPY